Lymphoplasmacytic lymphoma risk factors: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
| Line 13: | Line 13: | ||
|+ | |+ | ||
! colspan="2" |Risk factors for development of lymphoplasmacytic lymphoma | ! colspan="2" |Risk factors for development of lymphoplasmacytic lymphoma | ||
! | |||
|- | |- | ||
| colspan="2" |Pre-existing [[Monoclonal gammopathy of undetermined significance]] (MGUS) is the most common [[Risk factors|risk factor]], associated with 40 times more likelihood of developing [[lymphoplasmacytic lymphoma]]<ref name="RF" /> | | colspan="2" |Pre-existing '''[[Monoclonal gammopathy of undetermined significance]] (MGUS)''' is the most common [[Risk factors|risk factor]], associated with 40 times more likelihood of developing [[lymphoplasmacytic lymphoma]]<ref name="RF" /> | ||
| rowspan="9" |'''Non-modifiable factors''' | |||
|- | |- | ||
|Inherited immune disorders | |'''Inherited immune disorders''' | ||
| | | | ||
*[[Hypogammaglobulinemia]] | *[[Hypogammaglobulinemia]] | ||
*[[Wiskott-Aldrich syndrome]] | *[[Wiskott-Aldrich syndrome]] | ||
|- | |- | ||
|[[Heredity]]<ref name="pmid16357024" /><ref name="pmid17785558" /><ref name="pmid18703425" /> | |[[Heredity|'''Heredity''']]<ref name="pmid16357024" /><ref name="pmid17785558" /><ref name="pmid18703425" /> | ||
|[[Patients]] with [[lymphoplasmacytic lymphoma]] usually have a close/first-degree relative with the [[disease]] or with a related [[B-cell leukemia|B-cell disease]], such as [[MGUS]] or certain types of [[lymphoma]] or [[leukemia]] | |[[Patients]] with [[lymphoplasmacytic lymphoma]] usually have a close/first-degree relative with the [[disease]] or with a related [[B-cell leukemia|B-cell disease]], such as [[MGUS]] or certain types of [[lymphoma]] or [[leukemia]] | ||
|- | |- | ||
|[[Autoimmune Disease|Autoimmune Diseases]]<ref name="pmid18703425" /><ref name="pmid18809818" /><ref name="pmid18387498" /><ref name="pmid20181958" /><ref name="pmid18263783" /><ref name="pmid16985251" /> | | colspan="2" |'''[[Age]]'''>50 years | ||
|- | |||
| colspan="2" |'''Gender'''-[[Male]] | |||
|- | |||
| colspan="2" |'''[[Race]]'''-White | |||
|- | |||
|[[Autoimmune Disease|'''Autoimmune Diseases''']]<ref name="pmid18703425" /><ref name="pmid18809818" /><ref name="pmid18387498" /><ref name="pmid20181958" /><ref name="pmid18263783" /><ref name="pmid16985251" /> | |||
|Personal and [[family history]] of [[autoimmune diseases]] with [[autoantibodies]] and chronic [[immune]] stimulation leads to 2-3 fold higher risk of developing LPL, especially elevated [[risks]] are associated with following: | |Personal and [[family history]] of [[autoimmune diseases]] with [[autoantibodies]] and chronic [[immune]] stimulation leads to 2-3 fold higher risk of developing LPL, especially elevated [[risks]] are associated with following: | ||
*Chronic [[hepatitis C]] [[infection]] leads to an overall 20-30% increased risk for developing [[Non-Hodgkin lymphoma|non-Hodgkin lymohoma]] and 3-fold increased risk for [[lymphoplasmacytic lymphoma]] | *Chronic [[hepatitis C]] [[infection]] leads to an overall 20-30% increased risk for developing [[Non-Hodgkin lymphoma|non-Hodgkin lymohoma]] and 3-fold increased risk for [[lymphoplasmacytic lymphoma]] | ||
| Line 36: | Line 44: | ||
*[[Psoriasis]] | *[[Psoriasis]] | ||
|- | |- | ||
|[[Allergic]] conditions | |'''[[Allergic]] conditions''' | ||
|[[Hay fever]] is also known to be associated with increased risk of [[lymphoplasmacytic lymphoma]] | |[[Hay fever]] is also known to be associated with increased risk of [[lymphoplasmacytic lymphoma]] | ||
|- | |- | ||
|[[Environmental factor|Environmental factors]]<ref name="pmid20308603" /><ref name="pmid25174029" /> | | colspan="2" |'''[[Human]] T-lymphotrophic [[virus]] type I''' or '''[[Epstein Barr virus|Epstein-Barr virus]]''' | ||
|- | |||
|[[Environmental factor|'''Environmental factors''']]<ref name="pmid20308603" /><ref name="pmid25174029" /> | |||
|According to some recent studies, exposure to following [[environmental factor]]<nowiki/>s seems to have an [[Association (statistics)|association]] with the [[development]] of LPL: | |According to some recent studies, exposure to following [[environmental factor]]<nowiki/>s seems to have an [[Association (statistics)|association]] with the [[development]] of LPL: | ||
| Line 51: | Line 61: | ||
*Wood dust | *Wood dust | ||
*[[Organic solvents]] | *[[Organic solvents]] | ||
| rowspan="5" |'''Modifiable''' '''factors''' | |||
|- | |- | ||
| colspan="2" |History of '''[[Helicobacter pylori infection]]''' | |||
| colspan="2" |History of [[Helicobacter pylori infection]] | |||
|- | |- | ||
| colspan="2" |History of [[immunosuppressant]] [[Drugs|drug therapy]] after an [[organ transplant]] | | colspan="2" |History of '''[[immunosuppressant]] [[Drugs|drug therapy]]''' after an '''[[organ transplant]]''' | ||
|- | |- | ||
| colspan="2" |[[Diet]] rich in meat and [[fat]] | | colspan="2" |'''[[Diet]]''' rich in '''meat''' and '''[[fat]]''' | ||
|- | |- | ||
| colspan="2" |History of past treatment for [[Hodgkin's lymphoma|Hodgkin lymphoma]] | | colspan="2" |History of '''past treatment''' for '''[[Hodgkin's lymphoma|Hodgkin lymphoma]]''' | ||
|} | |} | ||
Revision as of 16:58, 21 February 2019
|
Lymphoplasmacytic lymphoma Microchapters |
|
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphoplasmacytic lymphoma risk factors On the Web |
|
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma risk factors |
|
Risk calculators and risk factors for Lymphoplasmacytic lymphoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
Common risk factors in the development of lymphoplasmacytic lymphoma are monoclonal gammopathy of undetermined significance, heredity, hepatitis C and other autoimmune disorders, allergic conditions like hay fever, multiple environmental factors, Human T-lymphotrophic virus type I or Epstein-Barr virus, history of Helicobacter pylori infection, history of immunosuppressant drug therapy after an organ transplant, diet rich in meat and fat and history of past treatment for Hodgkin lymphoma.
Risk Factors
Following are the common risk factors for development of lymphoplasmacytic lymphoma:[1][2][3][4][5][6][7][8][9][10][11]
| Risk factors for development of lymphoplasmacytic lymphoma | ||
|---|---|---|
| Pre-existing Monoclonal gammopathy of undetermined significance (MGUS) is the most common risk factor, associated with 40 times more likelihood of developing lymphoplasmacytic lymphoma[1] | Non-modifiable factors | |
| Inherited immune disorders | ||
| Heredity[2][3][4] | Patients with lymphoplasmacytic lymphoma usually have a close/first-degree relative with the disease or with a related B-cell disease, such as MGUS or certain types of lymphoma or leukemia | |
| Age>50 years | ||
| Gender-Male | ||
| Race-White | ||
| Autoimmune Diseases[4][5][6][7][8][9] | Personal and family history of autoimmune diseases with autoantibodies and chronic immune stimulation leads to 2-3 fold higher risk of developing LPL, especially elevated risks are associated with following:
| |
| Allergic conditions | Hay fever is also known to be associated with increased risk of lymphoplasmacytic lymphoma | |
| Human T-lymphotrophic virus type I or Epstein-Barr virus | ||
| Environmental factors[10][11] | According to some recent studies, exposure to following environmental factors seems to have an association with the development of LPL:
|
Modifiable factors |
| History of Helicobacter pylori infection | ||
| History of immunosuppressant drug therapy after an organ transplant | ||
| Diet rich in meat and fat | ||
| History of past treatment for Hodgkin lymphoma | ||
References
- ↑ 1.0 1.1 Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015
- ↑ 2.0 2.1 Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C; et al. (2006). "Characterization of familial Waldenstrom's macroglobulinemia". Ann Oncol. 17 (3): 488–94. doi:10.1093/annonc/mdj111. PMID 16357024.
- ↑ 3.0 3.1 McMaster ML, Csako G, Giambarresi TR, Vasquez L, Berg M, Saddlemire S; et al. (2007). "Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families". Clin Cancer Res. 13 (17): 5063–9. doi:10.1158/1078-0432.CCR-07-0299. PMID 17785558.
- ↑ 4.0 4.1 4.2 Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O (2008). "Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden". Blood. 112 (8): 3052–6. doi:10.1182/blood-2008-06-162768. PMC 2569164. PMID 18703425.
- ↑ 5.0 5.1 Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O (2008). "Chronic immune stimulation and subsequent Waldenström macroglobulinemia". Arch Intern Med. 168 (17): 1903–9. doi:10.1001/archinternmed.2008.4. PMC 2670401. PMID 18809818.
- ↑ 6.0 6.1 de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM; et al. (2008). "Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium". Clin Gastroenterol Hepatol. 6 (4): 451–8. doi:10.1016/j.cgh.2008.02.011. PMC 3962672. PMID 18387498.
- ↑ 7.0 7.1 Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I; et al. (2010). "Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia". J Natl Cancer Inst. 102 (8): 557–67. doi:10.1093/jnci/djq043. PMC 2857799. PMID 20181958.
- ↑ 8.0 8.1 Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J; et al. (2008). "Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium". Blood. 111 (8): 4029–38. doi:10.1182/blood-2007-10-119974. PMC 2288717. PMID 18263783.
- ↑ 9.0 9.1 Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH; et al. (2006). "Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia". J Natl Cancer Inst. 98 (18): 1321–30. doi:10.1093/jnci/djj361. PMID 16985251.
- ↑ 10.0 10.1 Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML (2010). "Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation". Blood. 115 (22): 4464–71. doi:10.1182/blood-2009-10-247973. PMC 2881498. PMID 20308603.
- ↑ 11.0 11.1 Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A; et al. (2014). "Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project". J Natl Cancer Inst Monogr. 2014 (48): 87–97. doi:10.1093/jncimonographs/lgu002. PMC 4155457. PMID 25174029.